Sustained Ketamine Effectiveness for Suicidal Ideation (SKESI)
This observational cohort study (n=128) will evaluate the sustained effectiveness of intravenous (IV) ketamine for suicidal ideation in adults experiencing a suicidal crisis due to major depressive disorder.
Detailed Description
This is a retrospective cohort using routinely collected medical records of patients who received IV ketamine infusions for suicidal crisis in the Emergency and Post-Emergency Psychiatric Department at University Hospital Montpellier.
Patients received one or more IV ketamine infusions as an add-on to depression treatment; psychometric assessments and systematic reassessments were performed twice in the month following the last infusion to monitor suicidality and clinical course.
Primary aim is to assess sustained effectiveness on suicidal ideation and behaviour in adults treated between June 2022 and March 2024 (n=128).
Study Protocol
Preparation
Dosing
Integration
Therapeutic Protocol
Study Arms & Interventions
IV ketamine
experimentalRetrospective cohort of patients treated with IV ketamine as part of routine emergency/post-emergency psychiatric care; infusions may be repeated.
Interventions
- Ketaminevia IV• repeated
IV ketamine infusions given as part of routine clinical care; dosing not specified in records.
Participants
Inclusion Criteria
- Patients treated with IV ketamine in the Psychiatric Emergency and Post-Emergency Department (University Hospital, Montpellier) in context of suicidal crisis
- Over 18 y.o.
Exclusion Criteria
- Opposition to data use
- Subject deprived of liberty (by judicial or administrative decision)
- Subject protected by law (guardianship or curatorship)
- Subject not affiliated to a social security system
Study Details
- StatusCompleted
- PhasePhase NA
- Typeobservational
- DesignNon-randomized
- Target Enrollment128 participants
- TimelineStart: 2023-12-01End: 2024-09-23
- Compound
- Topic